Results 101 to 110 of about 13,302,509 (331)

Screening for lung cancer: A systematic review of overdiagnosis and its implications

Molecular Oncology, EarlyView.
Low‐dose computed tomography (CT) screening for lung cancer may increase overdiagnosis compared to no screening, though the risk is likely low versus chest X‐ray. Our review of 8 trials (84 660 participants) shows added costs. Further research with strict adherence to modern nodule management strategies may help determine the extent to which ...
Fiorella Karina Fernández‐Sáenz, Laura de la Torre‐Perez, David R Baldwin, Carlijn van der Aalst, Mangesh Thorat, David Ritchie, Andre L Carvalho, Carolina Espina, Ivan Solà, Carlos Canelo‐Aybar, Moira Magdalena Pissinis, Pablo Alonso‐Coello, Ana Carolina Pereira Nunes Pinto   +12 more
wiley   +1 more source

Hospital-Based Coalition to Improve Regional Surge Capacity

Western Journal of Emergency Medicine, 2012
Introduction: Surge capacity for optimization of access to hospital beds is a limiting factor in response to catastrophic events. Medical facilities, communication tools, manpower, and resource reserves exist to respond to these events.
James M. Learning, Thomas E. Terndrup, R. Jerry Adams, Spencer Adoff   +3 more
doaj  

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Paraneoplastic Lupus Nephritis in a Child With Neuroblastoma Recurrence

Pediatric Blood &Cancer, EarlyView.
Gabriele Mortari, Caterina Costagliola, Marta Nebiolo, Francesca Parisi, Martina Morini, Katia Mazzocco, Gabriele Gaggero, Stefano Volpi, Stefania Sorrentino, Virginia Livellara   +9 more
wiley   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

Capacity Building to Improve Hospital Managers’ Performance in West Asia [PDF]

International Journal of Health Policy and Management, 2019
Leila Doshmangir, Amirhossein Takian
doaj   +1 more source

Knowledge, attitudes, and practices regarding China’s DRG payment policy among healthcare professionals in tertiary and secondary hospitals in Yunnan Province: a cross-sectional study

Frontiers in Public Health
BackgroundThe China Healthcare Security Diagnosis Related Groups (CHS-DRG) payment policy is a cornerstone of China’s transition to value-based healthcare.
Jian Yang, Jian Yang, Jian Yang, Dan Qin, Dan Qin, Dan Qin, Fan Li, Fan Li, Fan Li   +8 more
doaj   +1 more source

Decision letter for "Standardized Hospital Management of Pediatric Diabetic Ketoacidosis Reduces Frequency of Low Blood Glucose Episodes"

, 2021

openalex   +1 more source

The importance of determining SARS-CoV-2 N-Ag serodiagnostics for the management of COVID-19 pneumonia in hospital settings [PDF]

, 2021
Yu. S. Lebedin, O. V. Lyang, Anaida G. Galstyan, А. А. Пантелеева, Vsevolod V. Belousov, Д В Ребриков   +5 more
openalex   +1 more source

Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies

Molecular Oncology, EarlyView.
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck   +12 more
wiley   +1 more source